Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099489 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT00099489 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 67 participants.
The verdict
NCT00099489, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).
Interventions
- DRUG Interferon Beta-1a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2004-02 |
| Est. Completion | 2006-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099489
The ClinicalTrials.gov registry entry for NCT00099489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon Beta-1a is the first listed.
NCT00099489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099489 about?
NCT00099489 is a clinical study titled "Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)". The purpose of this study is to determine whether AVONEX (Interferon Beta-1a), when compared to placebo, reduces the total dose of IVIg that is administered after Visit 5 and through Visit 9 (Week 32, End of Study).
What is the current status of trial NCT00099489?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2004-02. Estimated completion is 2006-02.
What interventions are being tested in trial NCT00099489?
The interventions under investigation include: Interferon Beta-1a (DRUG).
Who is sponsoring clinical trial NCT00099489?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.